TY - JOUR
T1 - Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy
AU - van der Valk, M.E.
AU - Mangen, M. J.
AU - Severs, M.
AU - ten Have, M.
AU - Dijkstra, G.
AU - van Bodegraven, A.A.
AU - Fidder, H. H.
AU - de Jong, D.J.
AU - Pierik, M.
AU - van der Woude, C.J.
AU - Romberg-Camps, M.
AU - Clemens, C.H.
AU - Jansen, J.M.
AU - van de Meeberg, P. C.
AU - Mahmmod, N.
AU - Meulen van der-de Jong, A.E.
AU - Ponsioen, C. Y.
AU - Bolwerk, C.
AU - Vermeijden, J. R.
AU - Siersema, P.D.
AU - Leenders, M
AU - Oldenburg, B.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - BACKGROUND AND AIMS: More data are warranted on the economic impact of different treatment strategies in ulcerative colitis (UC) patients. We compared the costs and quality of life of UC patients with a pouch reconstruction, an ileostomy or anti-tumour necrosis factor alpha (TNFalpha) therapy. METHODS: UC patients filled out 3-monthly questionnaires for 2 years. Differences in 3-monthly healthcare costs, productivity costs and patient costs were tested using mixed model analysis. Quality of life was assessed employing the ) and the inflammatory bowel disease questionnaire (IBDQ). RESULTS: Out of 915 UC patients, 81 (9%) had a pouch and 48 (5%) an ileostomy, and 34 (4%) were on anti-TNFalpha therapy. Anti-TNFalpha-treated patients reported high UC related-healthcare costs per 3 months (euro5350). Medication use accounted for 92% of healthcare costs. UC-attributable healthcare costs were 3-fold higher in ileostomy patients compared with pouch patients (euro1581 versus euro407; p < 0.01). Main cost drivers in ileostomy patients were healthcare costs and ileostomy supplies (2 and 23% of healthcare costs, respectively). In pouch patients, the main cost driver was hospitalization, accounting for 50% of healthcare costs. Productivity loss did not differ between pouch and ileostomy patients (euro483 versus euro377; p < 0.23), but was significantly higher in anti-TNFalpha-treated patients (euro1085). No difference was found in IBDQ scores, but pouch patients were found to have higher quality-adjusted life years than ileostomy patients and anti-TNFalpha-treated patients (0.90 [interquartile range 0.78-1.00] versus 0.84 [0.78-1.00] and 0.84 [0.69-1.00], respectively; p < 0.01). CONCLUSION: Patients receiving anti-TNFalpha therapy reported the highest healthcare cost, in which medication use was the major cost driver. Ileostomy patients were three times more expensive than pouch patients due to frequent hospitalization and ileostomy supplies.
AB - BACKGROUND AND AIMS: More data are warranted on the economic impact of different treatment strategies in ulcerative colitis (UC) patients. We compared the costs and quality of life of UC patients with a pouch reconstruction, an ileostomy or anti-tumour necrosis factor alpha (TNFalpha) therapy. METHODS: UC patients filled out 3-monthly questionnaires for 2 years. Differences in 3-monthly healthcare costs, productivity costs and patient costs were tested using mixed model analysis. Quality of life was assessed employing the ) and the inflammatory bowel disease questionnaire (IBDQ). RESULTS: Out of 915 UC patients, 81 (9%) had a pouch and 48 (5%) an ileostomy, and 34 (4%) were on anti-TNFalpha therapy. Anti-TNFalpha-treated patients reported high UC related-healthcare costs per 3 months (euro5350). Medication use accounted for 92% of healthcare costs. UC-attributable healthcare costs were 3-fold higher in ileostomy patients compared with pouch patients (euro1581 versus euro407; p < 0.01). Main cost drivers in ileostomy patients were healthcare costs and ileostomy supplies (2 and 23% of healthcare costs, respectively). In pouch patients, the main cost driver was hospitalization, accounting for 50% of healthcare costs. Productivity loss did not differ between pouch and ileostomy patients (euro483 versus euro377; p < 0.23), but was significantly higher in anti-TNFalpha-treated patients (euro1085). No difference was found in IBDQ scores, but pouch patients were found to have higher quality-adjusted life years than ileostomy patients and anti-TNFalpha-treated patients (0.90 [interquartile range 0.78-1.00] versus 0.84 [0.78-1.00] and 0.84 [0.69-1.00], respectively; p < 0.01). CONCLUSION: Patients receiving anti-TNFalpha therapy reported the highest healthcare cost, in which medication use was the major cost driver. Ileostomy patients were three times more expensive than pouch patients due to frequent hospitalization and ileostomy supplies.
U2 - 10.1093/ecco-jcc/jjv134
DO - 10.1093/ecco-jcc/jjv134
M3 - Article
C2 - 26254056
SN - 1873-9946
VL - 9
SP - 1016
EP - 1023
JO - Journal of Crohn's & Colitis
JF - Journal of Crohn's & Colitis
IS - 11
ER -